申请人:——
公开号:US20040122089A1
公开(公告)日:2004-06-24
Analogs of andandamide and arvanil have been found to act preferential at CB
1
and AR
1
receptors, and at receptors other than CB
1
and AR
1
. The analogs provide analgesic effects in vivo, and are useful in pain management. In addition, the analogs may be used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications. Several of the anandamide and arvanil analogs are more potent than anandamide and arvanil.
已发现与anandamide和arvanil类似物作用于CB1和AR1受体时具有优先性,并且还作用于非CB1和AR1受体。这些类似物在体内提供镇痛效果,并在疼痛管理中有用。此外,这些类似物还可以用作抗增殖/抗肿瘤剂、血管扩张剂以及其他应用。几种anandamide和arvanil类似物比anandamide和arvanil更有效。